The Signal Edition
Analysis

Final IPO prospectuses by non-SPACs fell to 7 in September from 18

Final IPO prospectuses from non-blank-check issuers fell from 18 in July to 7 in September, then 10 in October and 2 in November so far.

The columned facade of the New York Stock Exchange building on Wall Street in New York City, with the statue of George Washington in front
Arild Vågen / Wikimedia Commons (CC BY-SA 4.0)

What the SEC filings show

Companies other than blank-check firms filed final IPO prospectuses (Form 424B4) for 7 offerings in September 2026, down from 18 in July, according to The Signal Edition's IPO tracker, which is built from SEC filings. The count was 10 in October and 2 in November through Nov. 16. The first six months of 2026 averaged 14.8 a month, with a peak of 23 in May. The Signal Edition read the tracker's data file on Nov. 17, 2026.[1]

By month, the count was 9 in January, 20 in February, 5 in March, 15 in April, 23 in May, 17 in June, 18 in July, 12 in August, 7 in September, 10 in October and 2 in November so far. September and October together averaged 8.5 a month, 43% below the first-half average. The tracker dates each offering by the day its final prospectus was filed, which can be later than the pricing date printed in the document: the Windward Bio prospectus, for example, is dated Nov. 12 and was filed Nov. 16.[1]

Ten of the 19 offerings counted from September through Nov. 16 carry drug-related industry codes in the SEC data the tracker uses: six under biological products and four under pharmaceutical preparations. The rest were spread across a bank, an insurer, a medical-device maker and several industrial and services companies.[1]

PreviouslyTSMC board approves up to $500 million each in Anthropic and OpenAI

The four most recent pricings

Aspen Neuroscience, Inc. filed its final prospectus on Oct. 30, 2026 for 9,375,000 shares at $15.00 each, a total of $140.6 million before underwriting discounts, with a Nasdaq Global Select Market listing under the symbol ASPE. Bambusa Therapeutics, Inc. filed the same day for 10,555,555 shares at $16.00, which The Signal Edition calculates as $168.9 million before discounts, to trade on Nasdaq as BBTX.[2][3]

On Nov. 16, 2026 Windward Bio Group AG filed for 10,294,117 common shares at $17.00, a total of $175.0 million before discounts, approved to list on Nasdaq as WWB. It also describes a concurrent $50.0 million private placement to Sanofi Foreign Participations B.V. at the same $17.00 price. vVARDIS Holding AG filed for 9,722,223 Class A ordinary shares at $18.00, which The Signal Edition calculates as $175.0 million, approved to list on the New York Stock Exchange as VVVV. Both prospectuses say the underwriters hold a 30-day option to buy more shares.[4][5]

The four offerings add up to $659.5 million before underwriting discounts and before any option shares, a figure The Signal Edition computed from the share counts and prices on the four prospectus covers.[2][3][4][5]

Registrations kept arriving

First filings of registration statements by the same kind of issuer did not fall as far. They averaged 27.5 a month in September and October, 15% below the 32.3 a month of the first half, and 14 were filed in November through Nov. 16. The data does not say why individual registrations did not lead to a final prospectus.[1]

What the count leaves out

The tracker's own blank-check flag misses companies whose names mark them as blank-check vehicles, such as TCGX Acquisition Corp. II and Southport Acquisition Corp. II, both counted in October. The Signal Edition removed every issuer flagged as a blank-check company or named with the words Acquisition, SPAC or Merger, which changes the totals. The tracker's monthly chart, which relies on its flag, shows 12 for October and higher counts for several earlier months, including 20 for January and 32 for February; its September and November counts match the ones above.[1]

A final prospectus is not the same as a conventional IPO. Roze AI Inc., counted in September, filed to register shares for resale by existing holders in a direct listing on the Nasdaq Capital Market. Verdera Energy Corp., also counted in September, registered 35,000,000 shares for a planned special distribution by its parent, enCore Energy Corp. Offering sizes differ widely, offerings that file no Form 424B4 are not counted, and a count of offerings says nothing about how much money was raised.[6][7][1]

What happens next

Anthropic, PBC filed Amendment No. 3 to its registration statement on Nov. 17, 2026 and a Form 8-A registering its Class A common stock with The Nasdaq Stock Market the same day. The amendment keeps the range at $70.00 to $78.00 a share for 825,000,000 shares and now says Anthropic has been approved to list on the Nasdaq Global Select Market as ANT, a statement on the filing's cover rather than a completed listing, where Amendment No. 2 on Nov. 10 said it had applied. The delivery date and the final price are still blank in the filing.[8][9][10]

At the range, the offering is worth $57.75 billion to $64.35 billion before fees, a figure The Signal Edition calculated by multiplying the share count by each end of the range. That is about 88 to 98 times the four offerings above combined, though the Anthropic total includes 23,648,646 shares sold by existing holders; the company itself is selling 801,351,354. The tracker lists Anthropic as not yet priced and will count it once the company files its Form 424B4. Earlier coverage is in the Nov. 10 article on the range.[8][1]

Timeline

  1. Anthropic, PBC first files its Form S-1; the tracker lists it as not yet priced.[1]

  2. Aspen Neuroscience ($15.00 a share) and Bambusa Therapeutics ($16.00) file final prospectuses.[2][3]

  3. Anthropic sets a range of $70.00 to $78.00 for 825,000,000 shares in Amendment No. 2.[10]

  4. Windward Bio Group ($17.00) and vVARDIS Holding ($18.00) file final prospectuses.[4][5]

  5. Anthropic files Amendment No. 3 and a Form 8-A for its Nasdaq listing; the range is unchanged.[8][9]

See more of our coverage in Google SearchAdd as preferred source

Sources

  1. The Signal Edition: IPO tracker: SEC filings to go public 2026-11-17
  2. U.S. Securities and Exchange Commission (EDGAR): Aspen Neuroscience, Inc. final prospectus (Form 424B4) 2026-10-30
  3. U.S. Securities and Exchange Commission (EDGAR): Bambusa Therapeutics, Inc. final prospectus (Form 424B4) 2026-10-30
  4. U.S. Securities and Exchange Commission (EDGAR): Windward Bio Group AG final prospectus (Form 424B4) 2026-11-16
  5. U.S. Securities and Exchange Commission (EDGAR): vVARDIS Holding AG final prospectus (Form 424B4) 2026-11-16
  6. U.S. Securities and Exchange Commission (EDGAR): Roze AI Inc. registration statement for a direct listing (Form F-1) 2026-05-11
  7. U.S. Securities and Exchange Commission (EDGAR): Verdera Energy Corp. registration statement for a special distribution (Form F-1) 2026-04-30
  8. U.S. Securities and Exchange Commission (EDGAR): Anthropic, PBC registration statement, Amendment No. 3 (Form S-1/A) 2026-11-17
  9. U.S. Securities and Exchange Commission (EDGAR): Anthropic, PBC registration of Class A common stock with Nasdaq (Form 8-A12B) 2026-11-17
  10. U.S. Securities and Exchange Commission (EDGAR): Anthropic, PBC registration statement, Amendment No. 2 (Form S-1/A) 2026-11-10

Spotted an error? Report a correction. Read how we work.